Use of immune checkpoint inhibitors in cancer patients with pre-existing sarcoidosis

Sang T. Kim, Xerxes Pundole, Ramona Dadu, Olivier Lambotte, Manuel Ramos-Casals, Maria E. Suarez-Almazor

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


Aim: To evaluate adverse events in cancer patients with pre-existing sarcoidosis receiving immune checkpoint inhibitors (ICIs). Patients & methods: We retrospectively reviewed cancer patients with sarcoidosis who underwent treatment with ICI to determine frequency of sarcoidosis flares. Results: 32 patients with sarcoidosis received ICIs The median time to ICI initiation was 7 years (range: 1 month to 51 years). One patient (3%) with a 20-year remote history of sarcoidosis developed a clinically symptomatic exacerbation after three doses of atezolizumab, with hilar lymphadenopathy, subcutaneous nodules, arthritis and uveitis. Atezolizumab was discontinued and prednisone initiated. She had a fluctuating course with two additional flares. Conclusion: Frequency of flares in patients with a remote history of sarcoidosis who receive ICIs is low.

Original languageEnglish (US)
Pages (from-to)465-475
Number of pages11
Issue number6
StatePublished - Apr 2021


  • PD-1
  • Sarcoidosis
  • atezolizumab
  • cancer immunotherapy
  • immune checkpoint inhibitor
  • immune-related adverse events

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology


Dive into the research topics of 'Use of immune checkpoint inhibitors in cancer patients with pre-existing sarcoidosis'. Together they form a unique fingerprint.

Cite this